TRCT
MTCR

Tower Research Capital (TRC)’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Tower Research Capital (TRC)’s Portfolio MTCR Stock Details MTCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-18,413
Closed -$8K – 6702
2022
Q4 		$8K Buy
18,413
+24
+0.1% +$10 ﹤0.01% 4515
2022
Q3 		$9K Buy
18,389
+13,457
+273% +$6.62K ﹤0.01% 4739
2022
Q2 		$2K Sell
4,932
-12,443
-72% -$6.03K ﹤0.01% 5681
2022
Q1 		$11K Buy
17,375
+15,386
+774% +$8.06K ﹤0.01% 4251
2021
Q4 		$1K Sell
1,989
-2,117
-52% -$3.77K ﹤0.01% 5996
2021
Q3 		$14K Buy
4,106
+1,174
+40% +$3.66K ﹤0.01% 4055
2021
Q2 		$12K Buy
2,932
+1,656
+130% +$6.85K ﹤0.01% 4302
2021
Q1 		$8K Sell
1,276
-1,181
-48% -$10.5K ﹤0.01% 4497
2020
Q4 		$19K Buy
+2,457
New +$22.5K ﹤0.01% 3915

Other funds holding MTCR

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Tower Research Capital (TRC)'s MTCR Position: Q1 2023 in Review

Tower Research Capital (TRC) sold out of Metacrine, Inc. Common Stock (MTCR) in Q1 2023, closing a stake of 18,413 shares — an estimated $8K sold.

Tower Research Capital (TRC) first reported a position in MTCR in Q4 2020 and held it in 9 quarters. The position peaked at $19K in Q4 2020. 5 funds tracked by Wall St. Rank hold MTCR as of Q1 2023.

  • Tower Research Capital (TRC) reported no remaining Metacrine, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 18,413 Metacrine, Inc. Common Stock shares in Q1 2023, an estimated $8K.
  • Tower Research Capital (TRC) first reported a position in Metacrine, Inc. Common Stock in Q4 2020 and held it in 9 quarters.
  • Tower Research Capital (TRC)'s Metacrine, Inc. Common Stock position peaked at $19K in Q4 2020.
  • 5 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q1 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2023, filed 9 May 2023.